Design: phase 3, randomised, double-blind, placebo-controlled, 2:1, with a 28-week open-label extension
Population: 407 adults with type 2 diabetes, HbA1c 7.0-10.5%, on diet and exercise alone for at least 8 weeks
Primary outcome: change in HbA1c from baseline at week 24
Effect: −1.3% vs −0.6%; least-squares mean difference −0.7% (95% CI −0.8 to −0.5), P < 0.0001

A phase 3, double-blind, placebo-controlled trial randomised 407 adults with type 2 diabetes inadequately controlled on diet and exercise, 2:1, to HTD1801 1,000 mg twice daily or placebo. Baseline HbA1c was 8.5% (69 mmol/mol) in both arms. At 24 weeks the HbA1c change was −1.3% with the drug against −0.6% with placebo, a least-squares mean difference of −0.7% (95% CI −0.8 to −0.5, P < 0.0001). Reductions held through 52 weeks in a 28-week open-label extension, with safety followed to 56 weeks.

The tolerability profile is the interesting part. Diarrhoea was the commonest adverse event at 9.6% against 0.7% on placebo, mostly at initiation and mostly mild to moderate. That is a different pattern from the incretins, and it is oral, twice daily, with no injection and no titration schedule of the kind that defeats adherence.

This is a drug-naive population by design, so the result says nothing about where the agent sits alongside metformin, an SGLT2 inhibitor or a GLP-1 receptor agonist. A 0.7% placebo-adjusted fall is a respectable monotherapy signal and roughly what a well-taken sulfonylurea or DPP-4 inhibitor delivers; it is well short of the incretin classes. Watch for the combination data before forming a view on where it would be used.

Warn about early diarrhoea if this class reaches your formulary — it clusters at initiation and settles
Do not read a monotherapy result as add-on evidence; the comparator here was placebo, not active therapy
Note that the trial excluded fasting plasma glucose above 13.9 mmol/L — this is not a rescue agent
No cardiovascular or renal outcome data exist for this agent

Why it matters

A twice-daily oral with a non-incretin mechanism would matter most where injectables are unaffordable — which is much of Indian practice.

The statistics, in plain English

The −0.7% figure is the difference between the arms, not the fall a patient would see — the drug arm fell 1.3%, but 0.6% of that happened on placebo too, through trial participation, diet and regression to the mean. A confidence interval of −0.8 to −0.5 excludes zero comfortably, so the effect is real; whether 0.7% is clinically worthwhile depends on what else the patient could be taking instead.